Cristofanilli Reviews CDK 4/6 Inhibitors in the Case of a Patient With ER-Positive Breast CancerJune 29th 2019
During a recent <em>Targeted Oncology </em>case-based peer perspectives live dinner event, Massimo Cristofanilli, MD, explained the options for treatment based on the case scenario of a woman with ER-positive breast cancer.<br />
Bekaii-Saab Considers TKI Therapy to Treat Patients With Advanced GI CancersJune 13th 2019
During a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation, Tanios Bekaii-Saab, MD, discussed with a group of physicians the treatment options for patients with gastrointestinal cancers and the characteristics that influence his decision making. Bekaii-Saab explained his clinical decisions based on the case scenario of one patient with colorectal cancer and one with hepatocellular carcinoma.
Anti-PD-L1 Therapy May Have Benefit in Aggressive Papillary Thyroid CancerMay 29th 2019
Patients with aggressive papillary thyroid cancer may be good candidates for treatment with anti–PD-(L)1 immunotherapy due to elevated levels of serum PD-L1, according to findings from a new study presented during the 2019 AACR-AHNS Head and Neck Cancer Conference.
FDA Lifts Partial Hold on AIM2CERV Trial of Investigational Immunotherapy Agent in Cervical CancerMay 15th 2019
The FDA has lifted the partial clinical hold placed on the phase III AIM2CERV trial, which is evaluating axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer, according to Advaxis, the developer of the investigational immunotherapy agent.
Study Findings Support Pelvic Radiation Therapy Over Vaginal Cuff Brachytherapy in Endometrial CancerMay 8th 2019
Treatment with vaginal cuff brachytherapy plus paclitaxel and carboplatin chemotherapy was not found to be superior to pelvic radiation therapy in patients with high-intermediate and high-risk early-stage endometrial cancer, according to findings from a phase III trial recently published in the <em>Journal of Clinical Oncology</em>.
Benefits of Salvage Autologous Stem Cell Transplantation in Multiple Myeloma May Outweigh Short-Term Effects on QoL and PainMay 8th 2019
Patient-reported outcomes from the phase III myeloma X trial suggested that although patients with relapsed multiple myeloma who received salvage autologous stem cell transplantation had an initial reduction in quality of life and experienced a greater impact of adverse events, they had better long-term outcomes compared with patients who received nontransplantation consolidation.
First Patient Dosed in Phase III Study of E-Selectin Antagonist Uproleselan in AMLApril 26th 2019
The first patient has been dosed in a phase III clinical trial investigating the addition of uproleselan (GMI-1271) to standard 7+3 chemotherapy in older patients with previously untreated acute myeloid leukemia.
Cohen Reviews Treatment Decisions for Patient With Newly Diagnosed MCLApril 24th 2019
During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with mantle cell lymphoma in the clinic.
Novel Immunotherapy Tebentafusp Granted Fast Track Designation for Metastatic Uveal MelanomaApril 12th 2019
The FDA has granted tebentafusp (IMCgp100) a fast track designation for the treatment of patients with HLA-A*0201-positive previously untreated metastatic uveal melanoma, according to Immunocore Limited, the company developing the novel immunotherapy agent.
Polymorphisms May Offer Promising Biomarkers to Predict Outcomes in Colorectal CancerApril 9th 2019
Although biomarker discovery has been a challenge in colorectal cancer, new findings suggest the presence of select polymorphisms may be promising in predicting treatment outcomes in patients with colorectal cancer.
T-Cell Lymphopenia Linked to Poor Prognosis in Advanced Thyroid CancerMarch 29th 2019
Recently published data from a retrospective study suggest that patients with thyroid cancer who have T-cell lymphopenia are more likely to have aggressive tumors. Investigators believe this information can be used to identify potential therapeutic targets in these patients.
Phase III Trial Launches to Investigate TTFields With Paclitaxel in Recurrent Ovarian CancerMarch 26th 2019
A pivotal phase III INNOVATE-3 trial investigating the efficacy of tumor-treating fields (TTFields; Optune) combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer has been initiated, according to Novocure, the company developing the device.
FDA Grants Etoposide Toniribate Orphan Drug Designation for Advanced Biliary CancerFebruary 25th 2019
The FDA has granted an orphan drug designation to the investigational agent etoposide toniribate for the treatment of patients with relapsed/refractory biliary tract cancer, according to Imbrium Therapeutics, the company developing the topoisomerase II inhibitor.
Four-Drug Regimen Demonstrates Promising First-Line Findings for Older Patients With MCLFebruary 19th 2019
The treatment regimen of rituximab, bendamustine, bortezomib, and dexamethasone demonstrated activity and a manageable safety profile as a first-line therapy for patients with mantle cell lymphoma aged 65 years or older, according to findings from a prospective, multicenter phase II study.
First Patient Enrolled in Phase III Study of Novel Agent Arfolitixorin in mCRCDecember 20th 2018
The first patient has been enrolled in the pivotal phase III AGENT trial, which is investigating arfolitixorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab compared with FOLFOX plus bevacizumab in patients with metastatic colorectal cancer, according to Isofol Medical AB, the company developing arfolitixorin.
Low-Dose Radiation As Effective as Standard Dose for Select Patients With Thyroid CancerNovember 27th 2018
Patients with thyroid cancer classified as having low risk of disease recurrence can be treated safely with a lower dose of radiation following surgery, compared with the standard higher dose, according to long-term findings from the HiLo trial presented at the National Cancer Research Institute (NCRI) Cancer Conference.
Meta-Analysis Examines Risk for Subsequent Malignancy After Radioiodine Therapy for Thyroid CancerNovember 24th 2018
More research is still needed to determine the risk of developing a subsequent malignant neoplasm following radioactive iodine treatment for thyroid cancer, according to findings that were presented during the Annual Meeting of the American Thyroid Association and published in <em>Thyroid</em>.
First Patient Dosed in Phase III Trial Evaluating Bemarituzumab in Gastric and GEJ CancersOctober 9th 2018
The first patient has been dosed in the phase III FIGHT trial investigating bemarituzumab (FPA144) combined with chemotherapy in patients with previously untreated advanced gastric or gastroesophageal junction cancer, according to Five Prime Therapeutics, the developer of the isoform-selective FGF receptor 2b antibody.
Annual AACR Progress Report Highlights Successes, Challenges Across US Cancer CareSeptember 17th 2018
While significant progress has been made in the fight against cancer, including a decline in cancer deaths, the number of people projected to be diagnosed with cancer is on the rise, and there is still more work to be done, according to the newly released American Association for Cancer Research Cancer Progress Report.
Expert Details "Intriguing" Findings With Entinostat/Pembrolizumab Combo in Advanced MelanomaAugust 15th 2018
Sanjiv S. Agarwala, MD, discusses the promising activity seen with the combination of pembrolizumab and entinostat in patients with advanced melanoma, according to initial results from the ongoing ENCORE 601 trial.
Apatinib/Chemotherapy Combination Achieves Durable Response in Platinum-Resistant/Refractory Ovarian CancerAugust 10th 2018
The combination of apatinib and oral etoposide showed promising efficacy and a manageable safety profile in patients with platinum-resistant or platinum-refractory ovarian cancer, according to findings from the phase II AEROC trial recently published in <em>The Lancet Oncology</em>.